ONX 0912 (PR-047)

Onyx is developing ONX 0912, an oral proteasome inhibitor based on the same novel chemistry as carfilzomib. ONX 0912 has demonstrated preclinical anti-tumor activity and a broad therapeutic window in animal models. ONX 0912 is currently in Phase 1 testing.